Peter Ferenci
Overview
Explore the profile of Peter Ferenci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
273
Citations
9315
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burghart L, Ferenci P, Petrenko O, Mandorfer M, Schwarz M, Gschwantler M, et al.
Aliment Pharmacol Ther
. 2024 May;
60(2):257-266.
PMID: 38798050
Background And Aims: Wilson's disease may progress to cirrhosis and clinically significant portal hypertension (CSPH). We aimed to assess the prevalence and prognostic impact of CSPH-related features on hepatic decompensation...
2.
Jachs M, Panzer M, Hartl L, Schwarz M, Balcar L, Camp J, et al.
JHEP Rep
. 2023 Jun;
5(8):100751.
PMID: 37360907
Background & Aims: Bulevirtide (BLV) is a novel antiviral drug licensed for the treatment of chronic hepatitis D. Data on the safety and efficacy of stopping BLV therapy upon long-term...
3.
Jachs M, Sauberer R, Stiegler A, Dechene A, Tazreiter R, Hartl L, et al.
United European Gastroenterol J
. 2023 Mar;
11(3):293-304.
PMID: 36965148
Background And Aims: Treatment indications for chronic hepatitis B (CHB) differ among recommendations by European Association for the Study of the Liver (EASL), American Association for the Study of Liver...
4.
Staufer K, Huber-Schonauer U, Strebinger G, Pimingstorfer P, Suesse S, Scherzer T, et al.
J Hepatol
. 2023 Mar;
78(5):1080-1083.
PMID: 36922250
No abstract available.
5.
Balcar L, Scheiner B, Urheu M, Weinberger P, Paternostro R, Simbrunner B, et al.
Dig Liver Dis
. 2023 Mar;
55(8):1072-1080.
PMID: 36863929
Background & Aims: Genetic factors such as the transmembrane 6 superfamily 2 (TM6SF2) rs58542926 single nucleotide variant(SNV) modulate the susceptibility for (advanced) chronic liver disease ([A]CLD). However, the impact of...
6.
Jachs M, Reiberger T, Ferenci P
Aliment Pharmacol Ther
. 2023 Jan;
57(3):359-360.
PMID: 36641789
No abstract available.
7.
Chromy D, Bauer D, Simbrunner B, Jachs M, Hartl L, Schwabl P, et al.
Infect Dis (Lond)
. 2022 Dec;
55(3):189-198.
PMID: 36484317
Background & Aims: Interferon(IFN)-based hepatitis C virus (HCV) therapy has been replaced by direct-acting antivirals (DAAs). We assessed temporal trends in patient characteristics, transmission risks, treatment initiation, and cure rates...
8.
Ferenci P, Reiberger T, Jachs M
Cells
. 2022 Nov;
11(22).
PMID: 36428959
HDV infection frequently causes progression to cirrhosis and hepatocellular carcinoma (HCC). In summer 2020, the first potentially effective drug Bulevirtide (BLV) has been approved for the treatment of HDV by...
9.
Balcar L, Scheiner B, Urheu M, Weinberger P, Paternostro R, Simbrunner B, et al.
JHEP Rep
. 2022 Sep;
4(11):100562.
PMID: 36176936
Background & Aims: Alpha-1 antitrypsin (AAT) deficiency causes/predisposes individuals to advanced chronic liver disease (ACLD). However, the role of the Pi∗Z allele in patients who have already progressed to ACLD...
10.
Jachs M, Reiberger T, Ferenci P
Aliment Pharmacol Ther
. 2022 Aug;
56(5):914-915.
PMID: 35934855
No abstract available.